Verified ComparisonLast updated: 24 April 2026
Semaglutide vs Liraglutide
Semaglutide and liraglutide are both GLP-1 receptor agonists, but differ in half-life and potency. Semaglutide's longer half-life and once-weekly dosing mark a shift in the GLP-1 class.
Semaglutide
Metabolic
4.3/ 5
A−
Liraglutide
Metabolic
4.1/ 5
A−
Editor's note
Semaglutide produces higher weight loss in head-to-head comparisons. Both are approved with robust CV outcome data.
| Criterion | Semaglutide | Liraglutide |
|---|---|---|
| Mechanism | GLP-1 agonist (high potency) | GLP-1 agonist (moderate potency) |
| Dosing frequency | Once weekly | Daily or weekly |
| Weight loss vs placebo | Superior in trials | Established benefit |
| Regulatory status (AU) | Approved | Approved |
| Cardiovascular outcomes data | Established (SELECT) | Established |
Frequently asked questions
Semaglutide was developed after liraglutide with improvements in potency and dosing.
Want to read the full reviews?